These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34967982)

  • 1. Trends in hospitalization and factors associated with in-hospital death among pediatric admissions with implantable cardioverter defibrillators.
    Qasim A; Dam T; Kim JJ; Valdes SO; Howard T; Diaz MA; Morris SA; Miyake CY
    J Cardiovasc Electrophysiol; 2022 Mar; 33(3):502-509. PubMed ID: 34967982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure.
    Chen CY; Stevenson LW; Stewart GC; Bhatt DL; Desai M; Seeger JD; Williams L; Jalbert JJ; Setoguchi S
    BMJ; 2015 Jul; 351():h3529. PubMed ID: 26174233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy.
    El Moheb M; Nicolas J; Khamis AM; Iskandarani G; Akl EA; Refaat M
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012738. PubMed ID: 30537022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators.
    Peterson PN; Greenlee RT; Go AS; Magid DJ; Cassidy-Bushrow A; Garcia-Montilla R; Glenn KA; Gurwitz JH; Hammill SC; Hayes J; Kadish A; Reynolds K; Sharma P; Smith DH; Varosy PD; Vidaillet H; Zeng CX; Normand ST; Masoudi FA
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?
    Ambrosy AP; Parzynski CS; Friedman DJ; Fudim M; Hernandez AF; Fonarow GC; Masoudi FA; Al-Khatib SM
    Circulation; 2018 Dec; 138(24):2787-2797. PubMed ID: 30565983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society.
    Silka MJ; Kron J; Dunnigan A; Dick M
    Circulation; 1993 Mar; 87(3):800-7. PubMed ID: 8443901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use and Outcomes of Dual Chamber or Cardiac Resynchronization Therapy Defibrillators Among Older Patients Requiring Ventricular Pacing in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.
    Borne RT; Masoudi FA; Curtis JP; Zipse MM; Sandhu A; Hsu JC; Peterson PN
    JAMA Netw Open; 2021 Jan; 4(1):e2035470. PubMed ID: 33496796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus.
    Sharma A; Wu J; Xu H; Hernandez A; Felker GM; Al-Khatib S; Green J; Matsouaka R; Fonarow GC; Singh JP; Heidenreich PA; Ezekowitz JA; DeVore A
    J Am Heart Assoc; 2020 Jun; 9(12):e012405. PubMed ID: 32476539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal Trends and Outcomes of Implantable Cardioverter Defibrillators in Heart Failure and Chronic Kidney Disease in the United States.
    Talha KM; Jain V; Yamani N; Fatima K; Rashid AM; Hernandez GA; Dani SS; Fudim M; Minhas AMK
    Curr Probl Cardiol; 2023 Apr; 48(4):101548. PubMed ID: 36566952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospitalization Rates, Prevalence of Cardiovascular Manifestations, and Outcomes Associated With Sarcoidosis in the United States.
    Patel N; Kalra R; Doshi R; Arora H; Bajaj NS; Arora G; Arora P
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29358190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease.
    Bansal N; Szpiro A; Reynolds K; Smith DH; Magid DJ; Gurwitz JH; Masoudi F; Greenlee RT; Tabada GH; Sung SH; Dighe A; Go AS
    JAMA Intern Med; 2018 Mar; 178(3):390-398. PubMed ID: 29404570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure.
    Elming MB; Nielsen JC; Haarbo J; Videbæk L; Korup E; Signorovitch J; Olesen LL; Hildebrandt P; Steffensen FH; Bruun NE; Eiskjær H; Brandes A; Thøgersen AM; Gustafsson F; Egstrup K; Videbæk R; Hassager C; Svendsen JH; Høfsten DE; Torp-Pedersen C; Pehrson S; Køber L; Thune JJ
    Circulation; 2017 Nov; 136(19):1772-1780. PubMed ID: 28877914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low body mass index but not obesity is associated with in-hospital adverse events and mortality among implantable cardioverter-defibrillator recipients: insights from the National Cardiovascular Data Registry.
    Hsu JC; Varosy PD; Bao H; Wang Y; Curtis JP; Marcus GM
    J Am Heart Assoc; 2012 Dec; 1(6):e003863. PubMed ID: 23316325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implantable cardioverter-defibrillator and wait-list outcomes in pediatric patients awaiting heart transplantation.
    El-Assaad I; Al-Kindi SG; Oliveira GH; Boyle GJ; Aziz PF
    Heart Rhythm; 2015 Dec; 12(12):2443-8. PubMed ID: 26247317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single chamber implantable cardioverter defibrillator compared to dual chamber implantable cardioverter defibrillator: less is more! Data from the German Device Registry.
    Bogossian H; Frommeyer G; Hochadel M; Ince H; Spitzer SG; Eckardt L; Maier SKG; Kleemann T; Brachmann J; Stellbrink C; Gonska BD; Kääb S; Senges J; Lemke B
    Clin Res Cardiol; 2020 Jul; 109(7):911-917. PubMed ID: 31823040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex and Race Disparities in Hypertrophic Cardiomyopathy: Unequal Implantable Cardioverter-Defibrillator Use During Hospitalization.
    Patlolla SH; Schaff HV; Nishimura RA; Geske JB; Dunlay SM; Ommen SR
    Mayo Clin Proc; 2022 Mar; 97(3):507-518. PubMed ID: 34893323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).
    Cheng A; Zhang Y; Blasco-Colmenares E; Dalal D; Butcher B; Norgard S; Eldadah Z; Ellenbogen KA; Dickfeld T; Spragg DD; Marine JE; Guallar E; Tomaselli GF
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1084-91. PubMed ID: 25273351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.
    Bilchick KC; Wang Y; Cheng A; Curtis JP; Dharmarajan K; Stukenborg GJ; Shadman R; Anand I; Lund LH; Dahlström U; Sartipy U; Maggioni A; Swedberg K; O'Conner C; Levy WC
    J Am Coll Cardiol; 2017 May; 69(21):2606-2618. PubMed ID: 28545633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
    Stavrakis S; Asad Z; Reynolds D
    J Cardiovasc Electrophysiol; 2017 Jun; 28(6):659-665. PubMed ID: 28316104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.